Tarello, W · Acta veterinaria Hungarica · 2003 · DOI
This study looked at blood test results from 117 pets (dogs and cats) diagnosed with a fatigue syndrome similar to ME/CFS in humans. The researchers found that many of these animals had low blood cell counts and low platelets, along with high muscle enzyme levels and unusual bacteria-like organisms in their blood. When treated with a specific arsenic-based medication, all the animals recovered completely and their immune systems improved.
This study provides evidence that CFS-like illnesses in animals share biological markers (elevated CK, blood abnormalities, potential infectious agents) with human ME/CFS, supporting the hypothesis that ME/CFS may have an infectious or immune component. The complete remission following targeted treatment suggests that immune dysfunction in CFS-like conditions may be treatable, offering potential therapeutic leads for human research.
This study does not establish that the micrococcus-like organisms or Staphylococcus are definitively causative of CFS-like illness; they may be markers or secondary findings. It also does not prove that arsenic-based therapy would be safe or effective in humans with ME/CFS, nor does it demonstrate that human and animal CFS-like syndromes share the same etiology. The observational, retrospective design cannot establish causation.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →